for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Adverum Biotechnologies Doses First Patient In Cohort 4 Of OPTIC Phase 1 Clinical Trial Of ADVM-022

April 27 (Reuters) - Adverum Biotechnologies Inc:

* ADVERUM BIOTECHNOLOGIES DOSES FIRST PATIENT IN COHORT 4 OF OPTIC PHASE 1 CLINICAL TRIAL OF ADVM-022 INTRAVITREAL GENE THERAPY FOR WET AMD Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up